Research Analysts’ Weekly Ratings Updates for Medtronic (MDT)

Several analysts have recently updated their ratings and price targets for Medtronic (NYSE: MDT):

• 11/20/2025 – Medtronic had its price target raised by analysts at Barclays PLC from $109.00 to $111.00. They now have an “overweight” rating on the stock.
• 11/20/2025 – Medtronic had its price target raised by analysts at Truist Financial Corporation from $103.00 to $110.00. They now have a “hold” rating on the stock.
• 11/19/2025 – Medtronic was given a new $111.00 price target on by analysts at Sanford C. Bernstein.
• 11/19/2025 – Medtronic was given a new $120.00 price target on by analysts at Leerink Partners. They now have an “outperform” rating on the stock.
• 11/19/2025 – Medtronic had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $110.00 price target on the stock.
• 11/19/2025 – Medtronic was given a new $111.00 price target on by analysts at The Goldman Sachs Group, Inc.. They now have a “neutral” rating on the stock.
• 11/19/2025 – Medtronic was upgraded by analysts at The Goldman Sachs Group, Inc. from a “sell” rating to a “neutral” rating. They now have a $111.00 price target on the stock, up previously from $81.00.
• 11/19/2025 – Medtronic had its price target raised by analysts at Morgan Stanley from $107.00 to $117.00. They now have an “overweight” rating on the stock.
• 11/19/2025 – Medtronic had its price target raised by analysts at Royal Bank Of Canada from $111.00 to $118.00. They now have an “outperform” rating on the stock.
• 11/19/2025 – Medtronic had its price target raised by analysts at UBS Group AG from $95.00 to $102.00. They now have a “neutral” rating on the stock.
• 11/19/2025 – Medtronic had its price target raised by analysts at Wells Fargo & Company from $100.00 to $114.00. They now have an “overweight” rating on the stock.
• 11/19/2025 – Medtronic had its price target raised by analysts at Robert W. Baird from $103.00 to $109.00. They now have a “neutral” rating on the stock.
• 11/14/2025 – Medtronic had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 11/14/2025 – Medtronic had its “neutral” rating reaffirmed by analysts at Piper Sandler.
• 11/13/2025 – Medtronic had its price target raised by analysts at JPMorgan Chase & Co. from $90.00 to $100.00. They now have a “neutral” rating on the stock.
• 11/2/2025 – Medtronic was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 10/31/2025 – Medtronic had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $98.00 price target on the stock.
• 10/25/2025 – Medtronic was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 10/15/2025 – Medtronic had its price target raised by analysts at Truist Financial Corporation from $96.00 to $103.00. They now have a “hold” rating on the stock.
• 10/10/2025 – Medtronic had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $111.00 price target on the stock.
• 10/9/2025 – Medtronic had its price target raised by analysts at Stifel Nicolaus from $90.00 to $105.00. They now have a “hold” rating on the stock.
• 10/8/2025 – Medtronic had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/7/2025 – Medtronic had its price target raised by analysts at Citigroup Inc. from $101.00 to $112.00. They now have a “buy” rating on the stock.
• 10/3/2025 – Medtronic was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 10/1/2025 – Medtronic had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $82.00 to $81.00. They now have a “sell” rating on the stock.
• 9/27/2025 – Medtronic had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity

In related news, Director William R. Jellison purchased 2,500 shares of Medtronic stock in a transaction on Monday, August 25th. The shares were bought at an average price of $92.37 per share, with a total value of $230,925.00. Following the transaction, the director directly owned 5,000 shares of the company’s stock, valued at approximately $461,850. This trade represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. The trade was a 19.46% decrease in their position. The SEC filing for this sale provides additional information. 0.26% of the stock is owned by corporate insiders.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.